Gene info: ID 4887

Gene: NPY2R

GENE ID: 4887

Synonyms: NPY2-R

Description: neuropeptide Y receptor Y2

Gene type: protein-coding

Location: 4q32.1

dbXrefs: Ensembl:ENSG00000185149 MIM:162642 Vega:OTTHUMG00000161485 UniprotKB:P49146

RefSeq: NC_000004.12

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD|ND|AD

# Publications: 5

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 3.343e-1 (AD) 7.526e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
KCNA4	0.759
SLC7A14	0.755
SSTR2	0.734
TUSC3	0.729
TENM3	0.728
SLC8A1	0.724
GSKIP	0.722
MKX	0.722
CXXC4	0.721
RGS17	0.718

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
ASB4	-0.505
SLC2A4	-0.501
MAPKAPK3	-0.488
FCGRT	-0.486
ZIC2	-0.482
GPRC5C	-0.479
PARD3B	-0.475
CYP11A1	-0.47
FKBP10	-0.465
NBPF10	-0.463

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00847	Cysteamine	Small Molecule	60-23-1	Approved\|Investigational	Target
DB05004	AC162352	Small Molecule	-	Investigational	Target
DB05045	Obinepitide	Small Molecule	348119-84-6	Investigational	Target

ID	Drug Name	Action	PubMed
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of NPY2R mRNA	22230336
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of NPY2R gene	27153756
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of NPY2R mRNA	16483693
C403256	BIIE 0246	BIIE 0246 binds to and results in decreased activity of NPY2R protein	15716408
C403256	BIIE 0246	BIIE 0246 results in decreased activity of NPY2R protein	18005069
C403256	BIIE 0246	[BIIE 0246 results in decreased activity of NPY2R protein] inhibits the reaction [NPY protein results in decreased susceptibility to Pilocarpine]	18005069
C006780	bisphenol A	bisphenol A results in decreased expression of NPY2R mRNA	25181051
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in decreased expression of NPY2R mRNA	26272509
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of NPY2R mRNA	23914054
D004041	Dietary Fats	Dietary Fats results in decreased expression of NPY2R mRNA	18721800
C118739	entinostat	entinostat results in decreased expression of NPY2R mRNA	26272509
C118739	entinostat	entinostat results in increased expression of NPY2R mRNA	27188386
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of NPY2R gene	16495775
C561695	(+)-JQ1 compound	(+)-JQ1 compound affects the expression of NPY2R mRNA	26733615
C561695	(+)-JQ1 compound	(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NPY2R mRNA]	26733615
C561695	(+)-JQ1 compound	panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NPY2R mRNA]	26733615
D007854	Lead	Lead affects the expression of NPY2R mRNA	28903495
C042720	mercuric bromide	mercuric bromide results in decreased expression of NPY2R mRNA	26272509
D008694	Methamphetamine	Methamphetamine affects the expression of NPY2R mRNA	15930374
D008694	Methamphetamine	NPY2R protein affects the reaction [NPY protein results in decreased susceptibility to Methamphetamine]	15930374
D008727	Methotrexate	Methotrexate results in decreased expression of NPY2R mRNA	24449571
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of NPY2R mRNA	23179753\|2627250
D015544	Inositol 1,4,5-Trisphosphate	"NPY2R protein affects the abundance of Inositol 1,4,5-Trisphosphate"	7742479
C483241	N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-(1-(2-cyclopentyl-ethyl)-piperidin-4yl)acrylamide	"N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-(1-(2-cyclopentyl-ethyl)-piperidin-4yl)acrylamide binds to and results in decreased activity of NPY2R protein"	14617685
C483241	N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-(1-(2-cyclopentyl-ethyl)-piperidin-4yl)acrylamide	"N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-(1-(2-cyclopentyl-ethyl)-piperidin-4yl)acrylamide binds to and results in decreased activity of NPY2R protein"	14617685
C496932	panobinostat	(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of NPY2R mRNA]	26733615
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C496932	panobinostat	panobinostat affects the expression of NPY2R mRNA	26733615
C496932	panobinostat	panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of NPY2R mRNA]	26733615
C496932	panobinostat	panobinostat results in decreased expression of NPY2R mRNA	26272509
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of NPY2R mRNA	26272509
D010862	Pilocarpine	[BIIE 0246 results in decreased activity of NPY2R protein] inhibits the reaction [NPY protein results in decreased susceptibility to Pilocarpine]	18005069
D010936	Plant Extracts	Plant Extracts results in decreased expression of NPY2R mRNA	23557933
C005556	propionaldehyde	propionaldehyde results in increased expression of NPY2R mRNA	26079696
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of NPY2R mRNA	25895662
C017947	sodium arsenite	sodium arsenite affects the methylation of NPY2R gene	28589171
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of NPY2R mRNA	21570461
D014212	Tretinoin	Tretinoin results in decreased expression of NPY2R mRNA	21934132\|2372400
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of NPY2R mRNA	24935251\|2627250
C012589	trichostatin A	trichostatin A results in increased expression of NPY2R mRNA	24935251
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NPY2R mRNA"	27188386
D014635	Valproic Acid	Valproic Acid results in decreased expression of NPY2R mRNA	23179753\|2438349
D014635	Valproic Acid	Valproic Acid results in decreased methylation of NPY2R gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of NPY2R mRNA	23179753\|2493525
D014635	Valproic Acid	Valproic Acid affects the expression of NPY2R mRNA	17963808
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of NPY2R gene	25560391
C111237	vorinostat	vorinostat results in decreased expression of NPY2R mRNA	26272509

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001601	peptide YY receptor activity	-	IEA	-
GO:0004983	neuropeptide Y receptor activity	-	TAS	7559383
GO:0005246	calcium channel regulator activity	-	TAS	8132547
GO:0005515	protein binding	-	IPI	23597562
GO:0038023	signaling receptor activity	-	TAS	1321422

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001662	behavioral fear response	-	IEA	-
GO:0002793	positive regulation of peptide secretion	-	IEA	-
GO:0003151	outflow tract morphogenesis	-	IMP	19593212
GO:0003214	cardiac left ventricle morphogenesis	-	IMP	19593212
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007193	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway	-	IEA	-
GO:0007204	positive regulation of cytosolic calcium ion concentration	-	IEA	-
GO:0007218	neuropeptide signaling pathway	-	IEA	-
GO:0007263	nitric oxide mediated signal transduction	-	IEA	-
GO:0007568	aging	-	IEA	-
GO:0007626	locomotory behavior	-	TAS	9692752
GO:0010811	positive regulation of cell-substrate adhesion	-	IEA	-
GO:0033603	positive regulation of dopamine secretion	-	IEA	-
GO:0043951	negative regulation of cAMP-mediated signaling	-	IEA	-
GO:0045987	positive regulation of smooth muscle contraction	-	IEA	-
GO:0046010	positive regulation of circadian sleep/wake cycle, non-REM sleep	-	IEA	-
GO:0046903	secretion	-	IEA	-
GO:0051048	negative regulation of secretion	-	IEA	-
GO:0051930	regulation of sensory perception of pain	-	IEA	-
GO:0051967	negative regulation of synaptic transmission, glutamatergic	-	IEA	-
GO:0090394	negative regulation of excitatory postsynaptic potential	-	IEA	-
GO:2000252	negative regulation of feeding behavior	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005622	intracellular	-	IEA	-
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IEA	-
GO:0097730	non-motile cilium	-	IEA	-

KEGG ID	KEGG Term
hsa04080	Neuroactive ligand-receptor interaction

Reactome ID	Reactome Term	Evidence
R-HSA-162582	Signal Transduction	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	TAS
R-HSA-375276	Peptide ligand-binding receptors	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-418594	G alpha (i) signalling events	TAS
R-HSA-500792	GPCR ligand binding	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
24268366	Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure. (2014 Jan)	Yang TY	Environ Res
27584037	Association between neuropeptide Y receptor Y2 promoter variant rs6857715 and major depressive disorder. (2017 Feb)	Treutlein J	Psychiatr Genet
16198492	Y1-receptors regulate the expression of Y2-receptors in distinct mouse forebrain areas. (2005)	Wittmann W	Neuroscience
20811389	Association between neuropeptide Y receptor 2 polymorphism and the smoking behavior of elderly Japanese. (2010 Nov)	Sato N	J Hum Genet
18828811	Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. (2008 Dec)	Wetherill L	Alcohol Clin Exp Res